SCHEMBL3007253

SCHEMBL3007253

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
TACR1 P25103 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RECQL P46063 2/20 0.36
USP2 O75604 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR6 P50406 1/20 0.36
POLB P06746 1/20 0.35
ADRB2 P07550 1/20 0.35
TSHR P16473 1/20 0.35
MCHR1 Q99705 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013679 0.93 MAPT (0.38) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3000012 0.91 CSNK1D (0.37) MAPTTACR1RECQLUSP2HSD17B10
SCHEMBL3021620 0.91 MAPT (0.45) KDM4EMAPTLMNATACR1RAB9A
SCHEMBL3001553 0.90 CMA1 (0.41) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3014518 0.90 MAPT (0.39) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3016023 0.89 NR1I2 (0.40) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3007192 0.89 SMN1; SMN2 (0.38) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3017438 0.89 KDM4E (0.43) KDM4EMAPTLMNARAB9ASMN1; SMN2
SCHEMBL3013307 0.89 KDM4E (0.40) KDM4ELMNARAB9ASMN1; SMN2MCHR1
SCHEMBL3011040 0.88 KDM4E (0.37) KDM4EMAPTLMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM4E 4398/4885MAPT 18/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.